Compare Fidelity National Information Servcs Inc (FIS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Twist Bioscience Corp — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Twist Bioscience Corp for 27 Days on average.
| FIS | TWST | |
|---|---|---|
Market Cap | $17.71B | $10.08B |
Volume | 9,047,825 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $67.94 | $205.00 |
52-Week Low | $32.44 | $25.45 |
Typical Hold Time | 88 Days | 27 Days |
Enterprise Value | $38.22B | $10.01B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
